Packaging Testing — Aging, Distribution & Sterile Barriers

A packaging programme should answer three separate questions: will the shipping unit protect its contents, will the primary package retain its required integrity, and will the packaged product remain suitable through its claimed storage period? Order the evidence for the actual product, not a generic bundle of tests.

Separate the shipping unit from the sterile barrier

A corrugated shipper, protective insert and sterile pouch have different functions. Distribution simulation stresses the complete shipping configuration; seal and integrity tests examine the barrier. A carton surviving a drop does not establish pouch integrity, and a strong seal does not show that transport leaves the device functional. Define the protection objective and the unit that each result represents before selecting methods.

Build a sequence around the labelled configuration

For medical-device packaging, identify ISO 11607 requirements alongside the sterilization process, aging rationale and transport route. ASTM D4169 organizes a distribution sequence; ASTM F1980 addresses time-related aging rather than every environmental hazard. Use representative product mass, packaging, closure and labelling. Agree whether aging precedes distribution and how baseline, post-aging and post-distribution integrity and device-function checks will be allocated.

Compare laboratories by the programme, not a test list

Ask how the provider chooses the distribution cycle, assurance level and inspection points, and whether barrier methods suit your porous or nonporous materials. Request the chamber and conditioning records, photographs of damage, deviations and individual specimen results. Outsourced transport testing and package-integrity work may occur at different sites: confirm responsibility for transfer, identification and reporting rather than assuming one site's scope covers the whole programme.

A package programme, not an automatic test bundle

Separate sterile-barrier performance and sealing-process validation from distribution protection. Seal strength measures separation force; integrity methods seek defects. Define baseline, sterilized, aged and transported groups and the product-function checks after each challenge. Under ASTM F1980, accelerated results require real-time confirmation. Aging addresses time-related change, not distribution performance, separate package-integrity evaluation or material-device interaction compatibility; temperature qualification is also a separate scope.

What to include in your buyer brief

Start with the decision the work must support. Unknown details can be clarified after the initial inquiry.

Product, materials/formulation, patient or drug contact, contact duration, intended use and target market; identify changed materials, suppliers or processes.
Finished configuration, sample count and lots, sterilization modality/cycles, aging and storage history; justify worst-case variants and destructive allocations.
Existing evaluation plan, drawings, specifications, methods/editions, previous reports and acceptance criteria; send confidential files only through the private intake.
Required report, quality/accreditation scope, budget range, location, shipping constraints and decision deadline; ask the provider to explain exclusions and subcontracted work.

Finished-product method pathways

Toys, bicycle assemblies, furniture and container/closure systems require category-specific evidence. Resin-coupon strength alone does not establish assembled-product safety. Packaging performance is separate from migration, food-contact compliance and microbial integrity.

Container & closure torque method selection: Manual torque retention, automated torque retention and torque-meter calibration address different measurement tasks. Define the cap/finish pair, liner, assembly process and retention question rather than requesting generic package safety.
Rigid-container & primary-package leak methods: Choose the defect question and package state before selecting vacuum, gross liquid leakage, mass extraction or visual inspection. Empty-container testing and filled-system performance are not interchangeable.
Child-resistant packaging method selection: Child-resistant performance concerns the complete package and intended opening/reclosing sequence, including human-panel testing where specified. Reclosable packs and non-reclosable pharmaceutical packs have distinct standards and type-approval context.

Sample considerations

Provide the finished shipping configuration, packaged device, material specifications, sterilization history and proposed shelf-life claim.
Supply drawings and closure settings; identify worst-case size, load and barrier variants with a documented rationale.
Agree destructive-test allocations, retained controls and real-time aging samples before shipment.

Questions to ask a laboratory

Which distribution cycle and assurance level represent our supply chain, and why?
Which barrier integrity methods are suitable for our materials, and how are controls demonstrated?
What accreditation scope and subcontracted work apply to this exact programme and location?

Laboratories with relevant capabilities

Keystone Package Testing (Coraopolis, PA) — Sterile Barrier Testing
Canyon Labs (Bluffdale, UT) — Sterile barrier integrity (bubble leak, dye penetration, peel strength, burst)
Tri-Wall UK (Monmouth, Wales) — Dangerous Goods Packaging Testing
Indian Institute of Packaging (Mumbai, Maharashtra) — Dangerous Goods Packaging Testing
Gaynes Laboratories (Bensenville, IL) — Dangerous Goods Packaging Testing

Frequently asked questions

What does ISO 11607 require?: It sets requirements for packaging of terminally sterilised medical devices, covering design, validation, performance and stability of the sterile barrier system.
How many packages are needed?: Sample size comes from the test standard and the statistical confidence needed for validation; the laboratory can advise once the plan is defined.